Preoperative induction with sorafenib pathologically downstaged advanced renal cell carcinoma: A case report

被引:3
作者
Kinoshita, Tatsuya [1 ]
Inoue, Hitoshi [1 ]
Kinouchi, Toshiro [1 ]
Kobayashi, Masao [1 ]
Takada, Tsuyoshi [1 ]
Hara, Tsuneo [1 ]
Hatano, Koji [2 ]
Nonomura, Norio [2 ]
机构
[1] Ikeda Municipal Hosp, Dept Urol, Ikeda, Osaka 5638510, Japan
[2] Osaka Univ, Grad Sch Med, Dept Urol, Osaka, Japan
关键词
multi-kinase inhibitor; preoperative; renal cancer; sorafenib; TARGETED THERAPY;
D O I
10.1111/j.1442-2042.2009.02444.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
We present the case of a patient with renal cell carcinoma treated preoperatively with sorafenib. Complete resection of the left renal mass measuring 7.2 x 6.6 cm seemed to be difficult at diagnosis because of large renal hilar lymph nodes. With a short period of sorafenib administration, marked shrinkage of the renal mass and lymphadenopathy was observed after the patient experienced fulminant hepatic failure and a severe hand-foot skin reaction. Two-dimensional computed tomography revealed 60%, 78% and 84% reduction in the primary renal tumor, lung metastatic nodules and lymph nodes, respectively. Tumor shrinkage allowed for complete resection of the left kidney and the lymphadenopathy. Pathological findings revealed that over 90% of the renal tumor was substituted by necrotic fibrotic tissue and that the residual neoplastic component was diagnosed as clear cell carcinoma. The lymph nodes that were resected were negative for malignancy. At 6 months after radical nephrectomy, a new computed tomography scan revealed no evidence of disease with the disappearance of lung nodules.
引用
收藏
页码:286 / 288
页数:3
相关论文
共 50 条
[41]   Colon perforation during sorafenib therapy for advanced hepatocelluar carcinoma. A case report [J].
Park, Sang-Gon ;
Chung, Choon-Hae ;
Park, Chi-Young .
TUMORI JOURNAL, 2011, 97 (06) :794-799
[42]   Axitinib for preoperative downstaging of renal cell carcinoma with sarcomatoid differentiation and direct invasion of the duodenum and inferior vena cava: a case report [J].
Yuki, Hideo ;
Kamai, Takao ;
Kubota, Keiichi ;
Abe, Hideyuki ;
Nishihara, Daisaku ;
Mizuno, Tomoya ;
Masuda, Akinori ;
Betsunoh, Hironori ;
Yashi, Masahiro ;
Fukabori, Yoshitatsu ;
Yoshida, Ken-Ichiro .
ONCOTARGETS AND THERAPY, 2014, 7 :289-295
[43]   Metastatic renal cell carcinoma: The first report of unilateral fundus hemorrhage induced by sorafenib [J].
Li, Zhi Yong ;
Fan, Xin Xiang ;
Wang, Yan Jun ;
Yao, Kai ;
Liu, Zhuo Wei ;
Pan, Wen Tao ;
Ye, Yun Lin ;
Yang, Ping ;
Huang, Yi Chuan ;
Wu, Zhi Ming ;
Zhou, Fang Jian .
ONCOTARGET, 2016, 7 (23) :35181-35187
[44]   Long-term response of over ten years with sorafenib monotherapy in metastatic renal cell carcinoma: A case report [J].
Ueda K. ;
Suekane S. ;
Ogasawara N. ;
Chikui K. ;
Suyama S. ;
Nakiri M. ;
Nishihara K. ;
Matsuo M. ;
Igawa T. .
Journal of Medical Case Reports, 10 (1)
[45]   Sorafenib improves the postoperative effect of early stage renal cell carcinoma [J].
Liu, Taiyang ;
Li, Jie ;
Wen, Xiuhua ;
Hui, Zhang ;
Qi, Gui .
ONCOLOGY LETTERS, 2016, 12 (06) :4367-4370
[46]   Treatment outcomes of sorafenib for first line or cytokinerefractory advanced renal cell carcinoma in Japanese patients [J].
Ueda, Takeshi ;
Imamura, Yusuke ;
Komaru, Atsushi ;
Fukasawa, Satoshi ;
Sazuka, Tomokazu ;
Suyama, Takahito ;
Naya, Yukio ;
Nihei, Naoki ;
Ichikawa, Tomohiko ;
Maruoka, Masayuki .
INTERNATIONAL JOURNAL OF UROLOGY, 2010, 17 (09) :811-815
[47]   Efficacy and safety of advanced renal cell carcinoma patients treated with sorafenib: roles of cytokine pretreatment [J].
Suzuki, Hisanori ;
Suzuki, Toshiro ;
Ishizuka, Osamu ;
Nishizawa, Osamu ;
Ueno, Manabu .
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2014, 19 (04) :686-692
[48]   Efficacy of sorafenib in advanced renal cell carcinoma independent of prior treatment, histology or prognostic group [J].
Tafreshi, Ali ;
Thientosapol, Eddy ;
Liew, Mun Sem ;
Guo, Yuan ;
Quaggiotto, Melissa ;
Boyer, Michael ;
Davis, Ian D. .
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 (01) :60-65
[49]   Cost-Effectiveness of Sorafenib for Second-Line Treatment of Advanced Renal Cell Carcinoma [J].
Hoyle, Martin ;
Green, Colin ;
Thompson-Coon, Jo ;
Liu, Zulian ;
Welch, Karen ;
Moxham, Tiffany ;
Stein, Ken .
VALUE IN HEALTH, 2010, 13 (01) :55-60
[50]   Critical appraisal of sorafenib in the treatment of Chinese patients with renal cell carcinoma [J].
Ye, Ding-Wei ;
Zhang, Hai-Liang .
ONCOTARGETS AND THERAPY, 2014, 7 :925-935